Program
AZD9550
A development code. Also written as “AZD9550 solution for injection”, “AZD9550 and AZD6234” and “AZD6234 in combination with AZD9550”.
Its studies are mostly in Obesity · Lymphoma, Follicular · Non-alcoholic Fatty Liver Disease, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 75 open or running | phase 2since Sep 22, 2023 | Mar 31, 2023 | Jan 29, 2027phase 2 · NCT06151964 |
- Named in AstraZeneca’s own pipeline as
AZD9550
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: quotient-sciences and parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 31, 2023First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05848440 · 48 enrolled · United Kingdom
- Sep 22, 2023Phase 2 study in OverweightNCT06151964 · 166 enrolled · Austria, Canada, Germany and more
- Feb 14, 2025Phase 2 study in ObesityNCT06862791 · 377 enrolled · United States, Australia, Canada and more
- May 14, 2025Phase 2 study in ObesityNCT07017179 · 16 enrolled · China
- Jun 2, 2025Phase 1 study in ObesityNCT07013643 · 100 enrolled · United States
- Mar 11, 2026Phase 1 study in Lymphoma, FollicularNCT07546760 · 28 planned · United States
- Sep 29, 2026Primary completion moved from 2026-08-06 to 2026-10-23Date moved laterphase 2 · +3 months · NCT07017179
- Oct 26, 2026Phase 1 study in ObesityNCT07911514 · 60 planned · United Kingdom
Ahead
- Jan 29, 2027Primary completion: phase 2 study in OverweightNCT06151964
- Feb 4, 2027Primary completion: phase 1 study in Lymphoma, FollicularNCT07546760
- May 4, 2027Primary completion: phase 1 study in ObesityNCT07911514
- Jul 9, 2027Primary completion: phase 1 study in ObesityNCT07013643
TargetBeta
“AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist.”study summary, read by Claude · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| DR10624rule | Huadong Medicine | phase 3 | 6 |
| efinopegdutide | Johnson & Johnson | phase 2 | 15 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07911514Obesity · United Kingdom | 1 | Not yet recruiting | May 4, 2027 | 60 |
| NCT07546760Lymphoma, Follicular · United States | 1 | Recruiting | Feb 4, 2027 | 28 |
| NCT07013643Obesity · United States | 1 | Active, not recruiting | Jul 9, 2027 | 100 |
| NCT07017179Obesity · China | 2 | Active, not recruiting | Oct 23, 2026 | 16 |
| NCT06862791Obesity · United States, Australia, Canada and more | 2 | Completed | May 11, 2026 | 377 |
| NCT06151964Overweight · Austria, Canada, Germany and more | 2 | Active, not recruiting | Jan 29, 2027 | 166 |
| NCT05848440Non-alcoholic Fatty Liver Disease · United Kingdom | 1 | Completed | Nov 13, 2023 | 48 |
How it is read
Names in the registry
- “AZD9550”, 7 entries
- “AZD9550 solution for injection”, 1 entry
- “AZD9550 and AZD6234”, 1 entry
- “AZD6234 in combination with AZD9550”, 1 entry
Codes read as this program: AZD9550.
Conditions, from the studies’ own filings
- Obesity, 5 studies
- Lymphoma, Follicular, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.